SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant downward pressure as disappointing delivery figures for the first quarter highlight growing concerns over demand and inventory buildup. The community remains deeply divided, with bears pointing to slowing EV sales and fading brand sentiment, while bulls continue to pivot the narrative toward the company's long-term ambitions in AI, robotics, and the potential impact of a future SpaceX IPO.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending due to intensifying acquisition speculation involving major tech titans, with community discourse fueled by leaked reports of Amazon buyout discussions and competing interests from SpaceX. Investors are actively debating the company's valuation, the strategic importance of its proprietary satellite spectrum, and the complex, multi-layered partnerships that make it a critical asset in the race for global direct-to-device connectivity.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing intense market activity as investors weigh its inclusion in the S&P 500 against concerns over its rapid share price appreciation and high valuation. While the community remains deeply divided between bulls citing AI infrastructure tailwinds and bears warning of a potential bubble, sentiment is currently driven by heavy options flow and anticipation of forced institutional buying.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently under intense scrutiny as investors debate whether recent network-related security incidents and market volatility present a buying opportunity or a signal of deeper structural weakness. While some in the community remain focused on developer momentum and potential institutional adoption through emerging clarity in stablecoin regulation, others express caution due to ongoing concerns about crypto-wide liquidity and the risks associated with altcoin exposure.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors weigh an earnings beat against concerns over leadership performance and persistent share price volatility. The community remains divided, with bulls pointing to the company's international growth and potential regulatory catalysts, while bears highlight ongoing cash burn, management frustrations, and a lack of clear federal progress.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing significant investor interest driven by strong fourth-quarter financial results, including substantial revenue growth and a strengthened balance sheet that has boosted confidence in its long-term turnaround strategy. The community is actively discussing potential catalysts such as the company's expansion into pharmaceutical manufacturing, participation in government-led reshoring initiatives, and ongoing speculation regarding its valuation as a specialized industrial and materials science player.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

KELYB is seeing intense community debate over its volatility and low-float structure, with bulls pointing to high institutional accumulation and potential squeeze scenarios while bears warn of extreme manipulation and risks after recent sharp price swings. Investors are closely watching for updates on the company's long-term strategy, specifically seeking clarity on how new ownership plans to unlock value from the firm's significant revenue base.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as the market anticipates the impact of its recently launched drug YARTEMLEA and ongoing developments surrounding a multi-billion dollar partnership with Novo Nordisk. Investors are closely tracking the company's progress on drug distribution, potential near-term milestone payments, and speculative buyout interest, while the community remains divided over short-term price volatility versus the stock's long-term growth potential.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is currently trending as investors speculate on its potential for a regulatory rebound following a previous FDA complete response letter (CRL) for its RP1 treatment in advanced melanoma. The community is heavily divided, with intense debate centered on the upcoming Type A meeting, the potential for an expedited path forward despite high hurdles, and significant high-risk activity in the options market as traders weigh the binary outcome of its long-term development plans.

SBA Communications Corp. is a real estate investment trust, which engages in the provision of wireless communications infrastructures. It operates through the following business segments: Domestic Site Leasing, International Site Leasing, and Site Development. The Domestic Site Leasing segment includes AT&T, Sprint, T-Mobile, and Verizon Wireless. The International Site Leasing segment acquires and develops towers. The Site Development segment is involved in consulting and construction activities. The company was founded by Steven E. Bernstein in 1989 and is headquartered in Boca Raton, FL.

SBA Communications Corp - Ordinary Shares - Class A

SBA Communications is currently attracting attention due to circulating buyout rumors and ongoing speculation regarding potential consolidation in the wireless infrastructure sector. While investors remain focused on the company's long-term 5G tailwinds and site leasing durability, community discourse is heavily weighed by concerns over high debt levels and the impact of interest rates on future profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LakeShore Biopharma Co., Ltd (LSB) on Thursday announced that its board of directors has received a revised preliminary non-binding proposal letter from a consortium to acquire all of the outstanding ordinary shares of the company in an all-cash transaction for $0.86 per ordinary share.The consortium is comprised of Oceanpine Investment Fund II LP, Oceanpine Capital Inc., and Crystal Peak Investment Inc. Members of the consortium currently beneficially own in aggregate approximately 52.1% of the company's issued and outstanding ordinary shares.The revised proposal letter, dated August 26, revises the preliminary non-binding proposal letter dated August 18, previously received from Oceanpine Capital.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LSB">LSB stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.LakeShore <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-receipt-of-a-revised-preliminary-non-binding-proposal-to-acquire-the-company-and-formation-of-special-committee-302541021.html">said</a> its board has formed a special committee consisting of its three independent directors, Adam Zhao, Thomas Xue, and Chunyang Shao, to evaluate and consider the revised proposal letter and transaction.The company has not made any decisions regarding its response to the proposal, it said, while adding that there is no assurance that a definitive offer will be made or an agreement executed.LakeShore said that the proposed purchase price per share of $0.86, which represents a premium of about 9% from the stock’s closing price on Wednesday, remains unchanged from the original proposal.The members of the consortium, however, have entered into an agreement to vote all of their shares in favor of the proposed transaction. They also do not intend to sell their shares to any third party or support any competing bid while remaining members of the consortium, LakeShore said.LSB stock is down by 77% this year and by 82% over the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-gdp-3-3-in-q2-revised-upwards-from-3/chs6JFbRdmZ">GDP Grows At 3.3% In Q2, Economy Expands At A Faster Clip Than Previously Estimated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

LakeShore Biopharma Receives Revised Proposal To Acquire Company

The company said the revised preliminary non-binding letter proposes the acquisition of all outstanding ordinary shares in an all-cash transaction for $0.86 apiece.

Equity

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee LakeShore Biopharma Announces Receipt of a Revised...

LakeShore Biopharma Co. (LSB) on Monday said that its board received a preliminary non-binding proposal letter to acquire all of the outstanding ordinary shares of the company for $0.86 per share.The proposal from Oceanpine Investment Fund II LP and Oceanpine Capital Inc. was dated August 18 and is for all shares not currently owned by Oceanpine Capital, the company said. The price of $0.86 represents a premium of 10.3% to the stock’s closing price on August 15.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-receipt-of-a-preliminary-non-binding-proposal-to-acquire-the-company-302532192.html">said</a> that the board will carefully review and evaluate the proposal to determine the future course of action. However, the board has not made any decisions on the proposal, and there is no assurance that any agreement will be executed, it added.On Stocktwits, retail sentiment about <a href="https://stocktwits.com/symbol/LSB">LakeShore</a> trended in the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Shares of the company traded 1% higher in the pre-market session at the time of writing.The proposed transaction will be funded with rollover equity and available cash on hand and will not be subject to a financing condition, Oceanpine said in its letter. “While we are fully prepared to work collaboratively with the Board to pursue the proposed transaction in a timely manner, we are open to exploring potential alternative structures of the Proposed Transaction to expedite the process of delivering value to the Company's shareholders,” Oceanpine said in its letter.LakeShore Biopharma operates in China, Singapore, and the Philippines. Its main product is a freeze-dried human rabies vaccine.LSB stock is down by 77% this year and by about 83% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tonix-pharma-stock-rises-pre-market-after-fda-approval-for-drug/chsO9FfRdXb">This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside 

The offer price of $0.86 represents a premium of 10.3% to the company's last closing price on August 15.

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

LakeShore Biopharma Co Ltd.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

LSB
LakeShore Biopharma Co Ltd.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest LSB News

LSBLakeShore Biopharma Co Ltd.